CEA antibody (full length) (CF®488A)

Catalog No. ABIN7877823

The Mouse Monoclonal anti-CEA antibody is suitable to detect CEA in samples from Human. It has been validated for IHC (p).

Quick Overview for CEA antibody (full length) (CF®488A) (ABIN7877823)

Target: CEA (Carcinoembryonic Antigen Gene Family (CEA))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CEA antibody is conjugated to CF®488A

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: C66-1009

Product Details anti-CEA Antibody (CF®488A)

Binding Specificity: full length

Purpose: CEA Antibody / Carcinoembryonic Antigen

Purification: Protein G affinity chromatography

Immunogen: Human full-length recombinant CEA protein was used as the immunogen for this antibody.

Isotype: IgG2a, kappa

Application Details

Application Notes: Optimal dilution of the CEA antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 500 µL at 0.1 mg/mL with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store the CEA antibody at 2-8oC, protected from light.

Target Details for CEA

Target: CEA (Carcinoembryonic Antigen Gene Family (CEA))

Alternative Name: CEA

Background: This antibody recognizes proteins of 80-200 kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70 % are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix.

UniProt: P06731